Are PLRZ insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PLRZ leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / PLRZ / insiders

DRIO (33) BEAT (42) NSPR (32) PMI (48) ⌘ Pro Terminal →

Polyrizon Ltd. (PLRZ) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$11.26 +4.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.33

Polyrizon Ltd. (PLRZ) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $26.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PLRZ Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PLRZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Polyrizon Ltd. (NASDAQ: PLRZ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $11.26 (+4.74% 1D, market cap $26.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PLRZ compare to DRIO and BEAT in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), PLRZ carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -25.1%. By comparison, DRIO (DarioHealth Corp.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $29.4M) and BEAT (Heartbeam Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $31.0M). Among the 5-stock peer group, PLRZ leads on earnings multiple (N/A) while PLRZ leads on capital efficiency (-25.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PLRZ?

▼

Per PLRZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001893645), Polyrizon Ltd. generated $17.5M in revenue (+380.0% YoY), -$3.3M in net income, and -$4.5M in free cash flow against $21.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $11.33 (+0.66%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PLRZ)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY PLRZ SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$9.74-6.1% Next Q

Q2 (-2Q)

Grade E$9.15-6.2% Next Q

Q3 (-1Q)

Grade E$8.58+31.2% Next Q

Current

Grade E$11.26-8.7% Hist 90D α

Trajectory: E (26) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PLRZ Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PLRZ currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.50) and Max Pain ($11.82) forces dealer call-delta covering toward $19.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PLRZ• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PLRZ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PLRZ Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PLRZ)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PLRZ. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PLRZ)

✓Walkthrough of PLRZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PLRZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.88%▼ DESCENDING CHANNEL

2026-11-03O $9.00H $11.26L $9.00C $11.26VOL 46.2K

RES: $13.57SUP: $7.61SMA50: $10.50SMA200: $12.58

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PLRZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PLRZ Butterfly Map → + Track PLRZ →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PLRZ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PLRZ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PLRZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PLRZ)

Health Care Rank #646 of 1016 ⚔️ DRIO vs PLRZ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PLRZ vs. DRIO, BEAT, NSPR, PMI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Polyrizon Ltd. (PLRZ) ranks #646 by composite RQD confidence (34/100, grade E) and #814 by equity capitalization ($26.1M). Within this direct 5-issuer industry benchmark cohort, PLRZ leads on earnings valuation at N/A trailing P/E, while PLRZ leads on capital efficiency and profitability with -25.1% ROIC and — gross margin. PMI currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with PLRZ at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PLRZ ACTIVE Polyrizon Ltd.	E	34/100	—	—	-25.1%	+4.74%	$26.1M	Benchmark Subject
DRIO DarioHealth Corp.	E	33/100	—	56.6%	-35.0%	+1.00%	$29.4M	/drio-vs-plrz →
BEAT Heartbeam Inc.	D-	42/100	—	—	-35.0%	-25.64%	$31.0M	/beat-vs-plrz →
NSPR InspireMD Inc.	E	32/100	—	29.5%	-35.0%	+19.78%	$20.9M	/nspr-vs-plrz →
PMI Picard Medical Inc.	D	48/100	—	—	—	+2.75%	$20.5M	/pmi-vs-plrz →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001893645

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Polyrizon Ltd. (PLRZ) reported GAAP revenue of $17.5M (+380.0% vs. FY2024 revenue of $3.6M , and +884.1% cumulative change since FY2023) , GAAP net income of -$3.3M, operating cash flow of -$4.5M, and free cash flow of -$4.5M (-295.4% YoY). On the balance sheet, PLRZ closed FY2025 with $21.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$17.5M	-$3.3M	-$4.5M	-$4.5M	$21.4M	—
FY2024 (FY)	2024-12-31	$3.6M	-$1.5M	-$1.1M	-$1.1M	$5.5M	—
FY2023 (FY)	2023-12-31	$1.8M	-$600.0K	-$537.0K	-$537.0K	—	—

3. PLRZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PLRZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PLRZ compare to DRIO and BEAT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PLRZ?

Where is PLRZ trading relative to its 50-day, 200-day, and 52-week technical levels?

PLRZ last traded at $11.26 (+4.74% on volume of 70,255 shares), positioning the stock +7.24% above its 50-day simple moving average ($10.50) and -10.49% below its 200-day simple moving average ($12.58). Across its 52-week range of $2.88 to $18.20, PLRZ sits at the 54.7% percentile with a 14-day RSI of 56.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($9.85 to $12.67).

Direct Sub-Reports: PLRZ RQD Cockpit PLRZ 12M Forecast PLRZ Earnings & Move PLRZ Dividends & DRIP PLRZ Insiders & 13F PLRZ Whale Options PLRZ Profit Sankey PLRZ News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PLRZ — Polyrizon Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:40Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

PLRZ carries an RQD Score of 30 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows: Fundamental Cash Engine 5/20 (ROIC -25.1%; FCF yield -20.74%), Whale/13F Flow 5/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 7/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The forensic balance sheet pillar is the highest of the five, but a Piotroski F-Score of 1 out of 9 signals weak financial quality on the scoring model's own terms. For a prospective investor, the upside case rests on factors not captured in the reported fundamentals, while the valuation tradeoff is that the price of $9 sits against negative ROIC and negative free cash flow yield. Investors should treat the rating as a forensic caution flag rather than a valuation signal.

2. Business Model, Unit Margins & SEC Financial Trajectory

Polyrizon Ltd. (PLRZ) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The profile lists a market capitalization of $0.0B, which conflicts with the $21.9M market cap reported in market data. Revenue is reported as — across all listed periods.

Reported operating and net losses widened from FY 2023 through FY 2025, with operating income moving from -$0.6M to -$6.2M. Gross, operating, and net margins are each reported as 0%, consistent with no reported revenue. Per the market data, ROIC is -25.1%, and the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9. Cash declined from $2.6M in FY 2024 to $1.3M in FY 2025, and debt is reported as N/A, with Debt/Equity of 0.5 .

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: The study of an experimental nasal allergy barrier has enrolled all 120 participants across five U.S. Sites. With Fundamental Cash Engine at 5/20 (ROIC -25.1%, FCF yield -20.74%) and Institutional Whale Flow at 9/20, sustained execution supports upside toward the top of the $2.88 – $18.20 52-week range.
🐻 Primary Bear Case: ROIC of -25.1% and FCF yield of -20.74% with reported revenue of $0.0M and a Piotroski F-Score of 1/9. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are therefore — The only cross-asset linkage in the source is the liquidity signal, which places PLRZ in the top decile of liquidity-sensitive equities by a 6.00x beta to net liquidity. Under that signal, a tightening of net liquidity would be expected to weigh on the stock more than on a typical equity, with the graph's bearish direction and 18/100 tailwind score pointing the same way. The correlation coefficient of +0.17 is low, so the liquidity link is a weak statistical relationship even with a high elasticity figure. Investors should watch for changes in the net liquidity index and in high-yield spreads as second-order inputs to this stock's sensitivity.

Key Question #1: What are the endpoints, timelines, and regulatory pathway for the nasal allergy barrier study, and how are they funded?
Key Question #2: The profile reports a $0.0B market capitalization while market data reports $21.9M. Which figure is correct?
Key Question #3: What is the company's cash runway given FY 2025 free cash flow of -$4.5M and year-end cash of $1.3M?

PLRZ Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Polyrizon Ltd. (PLRZ) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PLRZ Debate Forum (3) ↓

🟡 MARKET WIRE Stock Titan • 20h ago

A study of an experimental nasal allergy barrier has enrolled all 120 participants

Stock Titan report covering Polyrizon Ltd. (PLRZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 23h ago

Polyrizon (PLRZ) Holds the $10.00 Line as Momentum Stalls in a Flat Session - Stock Analysis

https://www.siam.in/ report covering Polyrizon Ltd. (PLRZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Across five U.S. sites, Polyrizon (PLRZ) completes enrollment in its nasal allergy study.

Stock Titan report covering Polyrizon Ltd. (PLRZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Polyrizon (PLRZ) Rises 4.56% to $9.00, Reclaiming the Middle of Its Recent Range - Profitability Factor

https://www.siam.in/ report covering Polyrizon Ltd. (PLRZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Polyrizon (PLRZ) Charges Higher by +1.33%, Clearing $9.44 2026-10-10 - Wyckoff Distribution

https://www.siam.in/ report covering Polyrizon Ltd. (PLRZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Polyrizon Ltd. (PLRZ) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Polyrizon Ltd. (PLRZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 6d ago

Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker

All 120 planned participants randomized across five clinical sites in the United States Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage bi

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 7d ago

Polyrizon Completes Participant Enrollment In Its Trial Of NASARIX To Treat Airborne Allergens

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced the successful

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PLRZ Bull vs. Bear Conversation Board — What's Your Call at $11.26?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PLRZ 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $14.08 (+31.0%)

📌 Pinned Debate

The study of an experimental nasal allergy barrier has enrolled all 120 participants across five U.S. sites.

Don't sleep on PLRZ's setup in Health Care. The study of an experimental nasal allergy barrier has enrolled all 120 participants across five U.S. sites.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (34/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA Fundamental Contrarian 🐻 BEARISH 🎯 Target: $9.24 (-14.0%)

Spot @ $10.75

ROIC of -25.1% and FCF yield of -20.74% with reported revenue of $0.0M and a Piotroski F-Score of 1/9.

Fading this rally in PLRZ at $10.75. ROIC of -25.1% and FCF yield of -20.74% with reported revenue of $0.0M and a Piotroski F-Score of 1/9.. With a beta of 1.0 and the stock sitting at $10.75 (52-wk range $2.88–$18.20), the easy multiple expansion is already priced in.